New Lo Loestrin Fe gets FDA approval
ARDEE, Ireland The Food and Drug Administration has approved a new contraceptive from Warner Chilcott, the drug maker said Friday.
The company said it plans to launch Lo Loestrin Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets) early next year. The company said the contraceptive contains the lowest dosage of estrogen — 10 micrograms — of any oral contraceptive currently available in the U.S. market.
“We are excited about the approval of Lo Loestrin Fe, which complements our women’s healthcare franchise and expands the product offerings in our branded oral contraceptive portfolio,” president and CEO Roger Boissonneault said in a statement.
Transcript Pharmacy receives ACHC accreditation
JACKSON, Miss. A pharmacy that specializes in serving patients with chronic medical conditions has received accreditation status from the Accreditation Commission for Health Care for specialty pharmacy services.
Transcript Pharmacy said Wednesday it was awarded ACHC accreditation, a voluntary activity where healthcare organizations submit to peer review of their internal policies, processes and patient care delivery against national standards. Transcript recently was involved in a year-long study conducted by Virginia Commonwealth University, which showed that through personalized communication with each patient, Transcript improved compliance.
“This recognition demonstrates that the level of care and quality of services we offer bring significant benefits to the patients that we serve,” said company president Cliff Osbon.
K-V establishes generic drug subsidiary Nesher Pharmaceuticals
ST. LOUIS K-V Pharmaceutical has created a new marketing subsidiary for generic drugs, the company said Wednesday.
K-V announced the establishment of Nesher Pharmaceuticals, appointing as its president Mark Hartman, who has had several positions in generic drug companies.
“Mark brings recognized depth and breadth of generic industry experience and leadership to K-V,” K-V interim president and CEO Greg Divis said. “We are excited to have Mark join our organization and look forward to him leading the introduction of Nesher Pharmaceuticals Inc., K-V’s new generic subsidiary.”